MCID: BLD131
MIFTS: 51

Bladder Urothelial Carcinoma malady

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Urothelial Carcinoma

Aliases & Descriptions for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 14
Transitional Cell Carcinoma of Bladder 12 29 69
Urinary Bladder Urothelial Carcinoma 12
Bladder Transitional Cell Carcinoma 12
Carcinoma Transitional Cell Bladder 52
Urothelial Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4006
NCIt 47 C39851
SNOMED-CT 64 255109008 393562002
UMLS 69 C0279680

Summaries for Bladder Urothelial Carcinoma

Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of bladder, is related to infiltrating bladder urothelial carcinoma sarcomatoid variant and clear cell variant infiltrating bladder urothelial carcinoma. An important gene associated with Bladder Urothelial Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and digestive/alimentary

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
id Related Disease Score Top Affiliating Genes
1 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.1
2 clear cell variant infiltrating bladder urothelial carcinoma 12.0
3 non-invasive bladder urothelial carcinoma 12.0
4 micropapillary variant infiltrating bladder urothelial carcinoma 12.0
5 lipid-cell variant infiltrating bladder urothelial carcinoma 12.0
6 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.0
7 nested variant infiltrating bladder urothelial carcinoma 12.0
8 microcystic variant infiltrating bladder urothelial carcinoma 12.0
9 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.0
10 transitional cell carcinoma 11.5
11 invasive bladder transitional cell carcinoma 11.2
12 linitis plastica 10.3 CDH1 TP53
13 chondrodysplasia punctata, rhizomelic, type 3 10.3 CASP3 TP53
14 polycystic bone disease 10.3 CCND1 FGFR3
15 bronchitis 10.3 CDH1 TP53
16 estrogen-receptor positive breast cancer 10.2 CCND1 CDH1 TP53
17 ideomotor apraxia 10.2 CCND1 CDH1 TP53
18 sarcomatoid basal cell carcinoma 10.2 CDH1 KRT20 TP53
19 gallbladder signet ring cell adenocarcinoma 10.2 CDH1 KRT20 TP53
20 maxillary sinus cholesteatoma 10.2 CCND1 CDH1 TP53
21 gastritis 10.2 CDH1 KRT20
22 clear cell hidradenoma 10.2 FGFR3 KRT20 TP53
23 spiradenoma 10.2 FGFR3 KRT20 TP53
24 progesterone-receptor positive breast cancer 10.2 CCND1 CDH1 TP53
25 embryonal testis carcinoma 10.2 CDH1 KRT20 UPK3A
26 type 1 papillary adenoma of the kidney 10.2 FGFR3 TP53 UPK3A
27 asperger syndrome 10.2 CCND1 CDH1 TP53
28 traumatic brain injury 10.2 CASP3 CDH1 TP53
29 uterine corpus endometrial stromal sarcoma 10.2 KRT20 TP53 UPK3A
30 fallopian tube adenocarcinoma 10.2 CASP3 KRT20 TP53
31 clitoris cancer 10.2 KRT20 UPK3A
32 oral squamous cell carcinoma 10.2 CDH1 KRT20 TP53
33 ovarian squamous cell carcinoma 10.2 CDH1 KRT20
34 pearson syndrome 10.2 CCND1 CDH1 TP53
35 cervical verrucous carcinoma 10.2 CCND1 RB1 TP53
36 breast malignant phyllodes tumor 10.2 CCND1 CDH1 TP53
37 extraocular retinoblastoma 10.2 CCND1 RB1 TP53
38 steroid-induced glaucoma - borderline 10.2 KLK3 KRT20
39 advanced sleep phase syndrome 10.2 CCND1 CDH1 KRT20 TP53
40 pituitary carcinoma 10.2 CCND1 CDH1 KRT20 TP53
41 integumentary system benign neoplasm 10.2 CCND1 RB1 TP53
42 connective tissue benign neoplasm 10.2 CASP3 CCND1 CDH1 TP53
43 malt worker's lung 10.2 KLK3 TP53
44 gastroesophageal junction adenocarcinoma 10.2 CCND1 CDH1 KRT20 TP53
45 ornithinemia 10.2 CASP3 CCND1 CDH1 TP53
46 post-surgical hypoinsulinemia 10.2 CCND1 RB1 TP53
47 trachea squamous cell carcinoma 10.2 CASP3 CCND1 CDH1 TP53
48 in situ pulmonary adenocarcinoma 10.2 CASP3 CCND1 CDH1 TP53
49 proctitis 10.2 CASP3 CCND1 CDH1 TP53
50 monoclonal paraproteinemia 10.2 CASP3 CDH1 KRT20

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CASP3 LDHB RB1 TNFRSF6B TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CASP3 CCND1 LDHB RB1 TNFRSF6B TP53

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 RB1 TP53 CASP3 CCND1 CDH1 FGFR3
2 integument MP:0010771 9.7 CASP3 CCND1 CDH1 FGFR3 FHIT RB1
3 neoplasm MP:0002006 9.5 AGGF1 CCND1 CDH1 FGFR3 FHIT RB1
4 reproductive system MP:0005389 9.23 CASP3 CCND1 CDH1 FGFR3 KIF11 RB1

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
4
Selenium Approved, Vet_approved Phase 3 7782-49-2
5
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
9
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
12
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
13
Aminolevulinic acid Approved Phase 3 106-60-5 137
14
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
15
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
16
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
17
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
18
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
19
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
20
Ethanol Approved Phase 3 64-17-5 702
21
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
22
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
23
Cephalexin Approved, Vet_approved Phase 3 15686-71-2 27447
24
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
27
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
28
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
29
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
30
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
33
Levulinic acid Experimental Phase 3 123-76-2 11579
34
Fenretinide Investigational Phase 3 65646-68-6
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 3,Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Antiviral Agents Phase 3,Phase 2,Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Liposomal amphotericin B Phase 2, Phase 3
41 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
42 Antioxidants Phase 3
43 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
44 Protective Agents Phase 3,Phase 2,Early Phase 1
45 Tocopherols Phase 3
46 Tocotrienols Phase 3
47 Trace Elements Phase 3,Phase 2,Phase 1,Early Phase 1
48 Vitamins Phase 3,Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Antimitotic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 345)
id Name Status NCT ID Phase
1 Cost-Effectiveness in Bladder Cancer Unknown status NCT00126958 Phase 4
2 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
3 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3
4 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3
5 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3
6 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3
7 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
8 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3
9 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
10 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3
11 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3
12 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3
13 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3
14 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3
15 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3
16 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
17 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3
18 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3
19 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
20 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
21 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3
22 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3
23 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3
24 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3
25 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
26 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3
27 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3
28 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
29 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
30 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3
31 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3
32 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3
33 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
34 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
35 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Recruiting NCT02853305 Phase 3
36 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
37 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3
38 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3
39 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3
40 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
41 Photodynamic Diagnosis (PDD) in Flexible Cystoscopy Recruiting NCT02660190 Phase 3
42 Tranexamic Acid During Cystectomy Trial (TACT) Recruiting NCT01869413 Phase 2, Phase 3
43 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
44 A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT Active, not recruiting NCT02563561 Phase 3
45 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3
46 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3
47 BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Terminated NCT00352079 Phase 3
48 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3
49 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3
50 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Terminated NCT00005047 Phase 3

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

id Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29

Anatomical Context for Bladder Urothelial Carcinoma

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

39
Bone, T Cells, Testes, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

18
The Lining Of The Bladder

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 67)
id Title Authors Year
1
A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. ( 28060759 )
2017
2
High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma. ( 27959455 )
2017
3
Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma. ( 27599849 )
2016
4
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. ( 26869805 )
2016
5
The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. ( 27341738 )
2016
6
Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. ( 27505309 )
2016
7
Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. ( 27181205 )
2016
8
Differential effects of adipose tissue stromal cells on the apoptosis, growth and invasion of bladder urothelial carcinoma between the superficial and invasive types. ( 27020040 )
2016
9
Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway. ( 27440446 )
2016
10
Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance. ( 27752905 )
2016
11
Evaluation of the role of immunohistochemical expression of EGFR (ERB B1) and HER4 (ERB B4) in urinary bladder urothelial carcinoma. ( 27772841 )
2016
12
Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma. ( 26852969 )
2016
13
Clarification of the molecular pathway of Taiwan local pomegranate fruit juice underlying the inhibition of urinary bladder urothelial carcinoma cell by proteomics strategy. ( 26955879 )
2016
14
Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience. ( 27563483 )
2016
15
A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. ( 26812572 )
2016
16
Retrospective study of various conservative treatment options with bacille Calmette-GuAcrin in bladder urothelial carcinoma T1G3: Maintenance therapy. ( 26922518 )
2016
17
Female, Black, and Unmarried Patients Are More Likely to Present With Metastatic Bladder Urothelial Carcinoma. ( 27212042 )
2016
18
E-cadherinA^CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas. ( 25826491 )
2015
19
Decrement of miR-199a-5p contributes to the tumorigenesis of bladder urothelial carcinoma by regulating MLK3/NF-I_B pathway. ( 26885275 )
2015
20
The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. ( 25940704 )
2015
21
Urinary bladder urothelial carcinoma with concurrent plasmacytoid and micropapillary differentiations: A report of two cases with an emphasis on serum carbohydrate antigen 19-9. ( 26044127 )
2015
22
The expression of AEG-1 and Cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance. ( 26885058 )
2015
23
T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. ( 26265374 )
2015
24
Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells. ( 26339359 )
2015
25
Significance of suppressor of cytokine signaling-3 expression in bladder urothelial carcinoma in relation to proinflammatory cytokines and tumor histopathological grading. ( 25640370 )
2015
26
Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues. ( 25422191 )
2014
27
Prognostic significance of Nestin expression in pT1 high- grade bladder urothelial carcinoma patients treated with intravesical BCG. ( 25605182 )
2014
28
Suppression of Cellular Proliferation and Invasion by HMGB1 Knockdown in Bladder Urothelial Carcinoma Cells. ( 26629935 )
2014
29
Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. ( 24462738 )
2014
30
Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. ( 25368291 )
2014
31
I+4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. ( 24388773 )
2014
32
A case of urinary bladder urothelial carcinoma with squamous, glandular, and plasmacytoid differentiation. ( 24987357 )
2014
33
Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance. ( 23613408 )
2013
34
PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. ( 24268029 )
2013
35
TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. ( 23277172 )
2013
36
Suppression of urinary bladder urothelial carcinoma cell by the ethanol extract of pomegranate fruit through cell cycle arrest and apoptosis. ( 24359437 )
2013
37
TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma. ( 24124001 )
2013
38
Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. ( 23696935 )
2013
39
Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. ( 23276457 )
2013
40
Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas. ( 22653741 )
2012
41
Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. ( 22261706 )
2012
42
hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. ( 21993544 )
2012
43
The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas. ( 22476051 )
2012
44
Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. ( 22249975 )
2012
45
Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma. ( 22685262 )
2012
46
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. ( 23107319 )
2012
47
The significance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma. ( 22613411 )
2012
48
Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma. ( 22173501 )
2011
49
Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. ( 22027740 )
2011
50
Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. ( 21388952 )
2011

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 87)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
4 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
20 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
21 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
24 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
25 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
26 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
27 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
28 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
29 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
30 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
31 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
32 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
33 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
34 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
35 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
36 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
37 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
38 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
39 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
40 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
41 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
42 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
43 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
44 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
45 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
46 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
47 MAP2K1 NM_002755.3(MAP2K1): c.371C> T (p.Pro124Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397516792 GRCh37 Chromosome 15, 66729163: 66729163
48 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
50 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275

Cosmic variations for Bladder Urothelial Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 16

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 CCND1 CDH1 FGFR3 FHIT KLK3 RB1
2 12.4 CASP3 CCND1 FGFR3 TP53
3 12.38 CCND1 KIF11 RB1 TP53
4
Show member pathways
12.35 CASP3 CCND1 CDH1 RB1 TP53
5 12.31 CCND1 CDH1 RB1 TP53
6
Show member pathways
12.31 CASP3 FGFR3 TGFBR3 TP53
7
Show member pathways
12.25 CASP3 CCND1 RB1 TP53
8 12.24 CCND1 CDH1 RB1 TP53
9
Show member pathways
12.22 CASP3 CCND1 CDH1 TP53
10 12.16 CASP3 CCND1 RB1 TP53
11
Show member pathways
12.12 CASP3 CCND1 RB1 TP53
12 12.1 CASP3 CCND1 CDH1 FGFR3 KLK3 RB1
13 12.01 CASP3 CCND1 CDH1 TP53
14 11.93 CCND1 TGFBR3 TP53
15
Show member pathways
11.87 CASP3 CCND1 FGFR3 RB1 TP53
16 11.85 CCND1 RB1 TP53
17 11.81 CASP3 CCND1 RB1 TP53
18 11.74 CCND1 KLK3 RB1
19 11.74 CASP3 CCND1 CDH1 RB1 TP53
20 11.72 CCND1 RB1 TP53
21 11.59 CCND1 FHIT RB1 TP53
22 11.44 CASP3 CCND1 TP53
23 11.41 CASP3 CCND1 TP53
24 11.39 CCND1 RB1 TP53
25 11.32 CASP3 RB1 TP53
26 11.04 CCND1 CDH1 TP53
27 10.96 CCND1 CDH1 FGFR3 RB1 TP53 UPK3A

GO Terms for Bladder Urothelial Carcinoma

Cellular components related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 AGGF1 CASP3 CCND1 CDH1 EMP2 FGFR3

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.5 CASP3 CCND1 CDH1
2 mitotic G1 DNA damage checkpoint GO:0031571 9.26 CCND1 TP53
3 apoptotic process GO:0006915 9.17 CASP3 FGFR3 FHIT KRT20 RB1 TNFRSF6B
4 glial cell apoptotic process GO:0034349 9.16 CASP3 RB1
5 response to X-ray GO:0010165 9.13 CASP3 CCND1 TP53

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 AGGF1 CASP3 CCND1 CDH1 EMP2 FGFR3
2 kinase binding GO:0019900 9.13 EMP2 LDHB RB1

Sources for Bladder Urothelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....